TKMR Key Stats
- Tekmira Announces Election of Directors noodls May 17
- Tekmira Presents LNP Technology Innovations at Scientific Symposium GlobeNewswire May 15
- Tekmira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcrip... May 14
- Tekmira Provides Corporate Update and Announces First Quarter 2013 Results GlobeNewswire May 14
- Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter... May 9
- Tekmira is on Track to Advance TKM-Ebola Program - Analyst Blog Zacks May 9
- Tekmira Recieves $140M Government Contract for TKM-Ebola Program Benzinga May 8
- Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program GlobeNewswire May 8
- The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy Apr 23
- Early-Stage Clinical Data Highlights From AACR 2013 Apr 17
TKMR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tekmira Pharmaceuticals Corporation is up 122.1% over the last year vs S&P 500 Total Return up 28.68%, Alnylam Pharmaceuticals up 176.7%, and DelMar Pharmaceuticals up 0.00%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for TKMR
Pro Report PDF for TKMR
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TKMR Pro Report PDF
Pro Strategies Featuring TKMR
Did Tekmira Pharmaceuticals Corporation make it into our Pro Portfolio Strategies?